Amneal wins US FDA approval for Rivastigmine Transdermal System
15 January 2019 -

Amneal Pharmaceuticals Inc (NYSE:AMRX) disclosed on Monday the receipt of US FDA approval for the generic version of the transdermal product Exelon Patch (Rivastigmine Transdermal System) in 4.6 mg/24 hours, 9.5 mg/24 hours and 13.3 mg/24 hours.

Following US FDA approval, the company said it intends to launch its Rivastigmine Transdermal System shortly.

For the 12 months ended November 2018, the US market annual sales for Rivastigmine Transdermal System is estimated at about USD225m, according to IQVIA,

Headquartered in Bridgewater, NJ, Amneal is a pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products.